Aminophylline inhibits which of the following enzymes?
A 60-year-old with COPD develops tremor after a medication. Which medication is most likely responsible?
The activation of muscarinic receptors in bronchiolar smooth muscle is associated with:
A 3-year-old is diagnosed with severe acute asthma exacerbation. Which medication is given first?
Which of the following drugs is commonly used as a rescue medication for acute asthma attacks?
Which agent stimulates both beta-1 and beta-2 receptors?
The following drug antagonizes the visceral side effects of neostigmine used for reversal of vecuronium blockade:
In comparison to inhaled adrenergic agonists, the inhaled anticholinergics:
Ocular effects that include mydriasis are characteristic of which of the following drugs?
Hippus occurs in which poisoning?
Explanation: ***Phosphodiesterase*** - **Aminophylline** is a methylxanthine derivative that primarily acts as a **phosphodiesterase (PDE) inhibitor** [1], [2]. - By inhibiting PDE, aminophylline increases intracellular levels of **cAMP** and **cGMP**, leading to **bronchodilation** and other effects [2], [3]. *MAO* - **MAO (monoamine oxidase)** inhibitors are antidepressants that prevent the breakdown of neurotransmitters like serotonin, norepinephrine, and dopamine. - Aminophylline does not significantly inhibit MAO. *Alcohol dehydrogenase* - **Alcohol dehydrogenase** is an enzyme responsible for metabolizing alcohol (ethanol) in the liver. - Aminophylline has no direct inhibitory effect on alcohol dehydrogenase. *Cytochrome P450* - **Cytochrome P450 (CYP450)** enzymes are a group of enzymes primarily involved in the metabolism of drugs and other xenobiotics in the liver [4]. - While aminophylline (and its active metabolite theophylline) can be metabolized by and *affect* certain **CYP450** isoenzymes (e.g., CYP1A2), it does not act as a general inhibitor of the entire CYP450 system; its primary therapeutic action is not through CYP450 inhibition.
Explanation: ***Salmeterol*** - Salmeterol is a **long-acting beta-2 agonist (LABA)** commonly used in COPD [1]. Beta-2 agonists can cause **tremor** due to stimulation of skeletal muscle beta-2 receptors [2]. - This side effect is dose-dependent and more common with higher doses or in sensitive individuals. *Montelukast* - Montelukast is a **leukotriene receptor antagonist** used in asthma and allergic rhinitis, not typically a primary agent for COPD, and does not commonly cause tremor. - Its mechanism of action involves blocking leukotriene D4 receptors, which are not directly linked to muscle tremor. *Ipratropium* - Ipratropium is a **short-acting muscarinic antagonist (SAMA)** used in COPD. Its primary side effects are typically anticholinergic, such as dry mouth or blurred vision [3]. - Tremor is not a common or expected side effect of ipratropium as it does not act on beta-adrenergic receptors. *Fluticasone* - Fluticasone is an **inhaled corticosteroid (ICS)** used in COPD, often in combination with LABAs [1]. While systemic corticosteroids can cause tremor, the inhaled form has minimal systemic absorption. - **Inhaled corticosteroids** are primarily associated with local side effects like oral candidiasis or dysphonia.
Explanation: ***Increase in IP3 and DAG*** - **Muscarinic receptors** on bronchial smooth muscle (M3 receptors) are **Gq protein-coupled receptors** [1]. - Activation of **Gq proteins** leads to the activation of **phospholipase C**, which hydrolyzes **PIP2** into **IP3** and **DAG** [1, 3]. *Inhibition of protein kinase C* - **DAG** (diacylglycerol), produced from the breakdown of PIP2, **activates protein kinase C (PKC)**, rather than inhibiting it [2]. - This activation of PKC contributes to downstream cellular responses, including smooth muscle contraction [1]. *Activation of adenylyl cyclase* - **Adenylyl cyclase** is typically activated by **Gs protein-coupled receptors**, leading to an increase in **cAMP**. - **Muscarinic (M3) receptors** are **Gq-coupled**, so they do not activate adenylyl cyclase; instead, they operate through the phospholipase C pathway [1, 3]. *Opening of Na+/K+ cation channels* - While some neurotransmitter receptors are **ligand-gated ion channels** (e.g., nicotinic receptors), muscarinic receptors are **G protein-coupled receptors** [1]. - Their activation does not directly lead to the opening of **Na+/K+ cation channels**; rather, they initiate intracellular signaling cascades.
Explanation: ***Nebulized salbutamol*** - **Salbutamol** (albuterol) is a **short-acting beta-2 agonist (SABA)** which provides rapid bronchodilation by relaxing smooth muscles in the airways. - It is the **first-line treatment** for acute asthma exacerbations due to its quick onset of action and effectiveness in relieving bronchospasm. *Inhaled ipratropium* - **Ipratropium**, an anticholinergic, is often added to bronchodilators like salbutamol in **severe exacerbations** but is not the primary initial bronchodilator. - It works by blocking muscarinic receptors, causing **bronchodilation**, but its onset of action is slower than salbutamol. *IV corticosteroids* - **Corticosteroids** reduce airway inflammation and are crucial for preventing relapse and shortening recovery in severe asthma, but their **onset of action is delayed** (several hours). - They are typically administered after initial bronchodilation with SABAs and are not the first medication given for immediate symptom relief. *IV magnesium sulfate* - **Magnesium sulfate** is a smooth muscle relaxant that can be used in **severe, life-threatening asthma exacerbations** that are refractory to standard therapy. - It is considered a **second or third-line treatment** rather than an initial intervention for immediate bronchodilation.
Explanation: ***Salbutamol*** - **Salbutamol** (albuterol) is a **short-acting beta-2 agonist (SABA)** that rapidly relaxes bronchial smooth muscle. - Its quick onset of action makes it ideal for immediate relief of **bronchoconstriction** during an acute asthma attack. - It is the **most commonly used** and **first-line rescue medication** for acute asthma worldwide. *Terbutaline* - **Terbutaline** is also a **short-acting beta-2 agonist (SABA)** similar to salbutamol and can be used as a rescue medication. - While it has comparable bronchodilator effects, **salbutamol is more commonly used** as the preferred rescue inhaler in clinical practice. - Both are SABAs, but salbutamol has become the standard first-choice rescue medication globally. *Theophylline* - **Theophylline** is a **methylxanthine** that acts as a bronchodilator but has a **narrow therapeutic index** and slower onset of action. - It is used as a **maintenance therapy** for chronic asthma and not as a rescue drug for acute exacerbations. *Budesonide* - **Budesonide** is an **inhaled corticosteroid (ICS)** used as a **long-term controller medication** to reduce airway inflammation. - It has a slow onset of action and is *not* effective for immediate relief during an acute asthma attack.
Explanation: ***Epinephrine*** - **Epinephrine** is a potent agonist at both **beta-1 (β1)** and **beta-2 (β2)** adrenergic receptors, leading to widespread sympathetic nervous system effects. - Its β1 stimulation increases **heart rate** and **contractility**, while β2 stimulation causes **bronchodilation** and vasodilation in certain vascular beds. *Dopamine* - **Dopamine** acts on different receptors depending on the dose: at low doses, it primarily activates **D1 receptors** (renal vasodilation), at intermediate doses, it activates **β1 receptors** (cardiac stimulation), and at high doses, it activates **α1 receptors** (vasoconstriction). - It does not significantly stimulate **beta-2 receptors** at therapeutic concentrations, distinguishing it from epinephrine. *Dobutamine* - **Dobutamine** is a synthetic catecholamine that acts primarily as a **β1-selective agonist**, significantly increasing **myocardial contractility** and heart rate. - While it has some weak β2 agonist activity, its predominant effect is on **β1 receptors**, making it less effective for widespread β2 stimulation compared to epinephrine. *Albuterol* - **Albuterol** is a **short-acting β2-adrenergic agonist** primarily used in the treatment of **asthma** to induce **bronchodilation**. - It has a high selectivity for **β2 receptors** in the lungs and has minimal effects on **β1 receptors** at therapeutic doses.
Explanation: ***Atropine*** - **Atropine** is an **anticholinergic drug** that blocks muscarinic receptors, effectively counteracting the **parasympathomimetic side effects** of neostigmine. - When neostigmine is used to reverse neuromuscular blockade, it inhibits **acetylcholinesterase**, increasing acetylcholine levels. This increased acetylcholine stimulates both nicotinic receptors (for muscle contraction) and muscarinic receptors (causing side effects like **bradycardia**, **salivation**, **bronchospasm**, and **gastrointestinal hypermotility**). Atropine selectively blocks these unwanted muscarinic effects. *Pilocarpine* - **Pilocarpine** is a **direct muscarinic agonist**, meaning it would exacerbate, rather than antagonize, the visceral side effects of neostigmine. - It is primarily used to treat **xerostomia** and **glaucoma** by increasing acetylcholine's effects on muscarinic receptors. *Pyridostigmine* - **Pyridostigmine** is another **cholinesterase inhibitor**, similar to neostigmine, and also used for reversal of neuromuscular blockade or in treating **myasthenia gravis**. - It would increase acetylcholine levels and thus enhance, not antagonize, the muscarinic side effects if used with neostigmine in this context. *Nicotine* - **Nicotine** is an agonist primarily acting on **nicotinic acetylcholine receptors**. - While neostigmine increases acetylcholine at nicotinic receptors to reverse muscle blockade, nicotine's primary action is not on muscarinic receptors to counteract the visceral side effects.
Explanation: ***Produce a slower response in bronchial asthma*** - **Inhaled anticholinergics** (e.g., ipratropium, tiotropium) block **muscarinic receptors**, leading to bronchodilation, but their onset of action is generally **slower** (15-30 minutes) compared to the rapid action of **beta-2 adrenergic agonists** (5 minutes). - This slower response makes them less ideal for **acute asthma attacks** where immediate bronchodilation is critical. - Anticholinergics are used as **add-on therapy** in asthma management. *Are more effective in bronchial asthma* - **Inhaled beta-2 adrenergic agonists** (e.g., salbutamol, albuterol) are typically **more effective** and are the **first-line treatment** for acute bronchodilation in asthma due to their rapid onset and potent effect. - **Anticholinergics** are often considered **add-on therapy** for asthma, particularly for patients who have an inadequate response to beta-agonists. *Produce little benefit in chronic obstructive lung disease* - **Inhaled anticholinergics** (e.g., tiotropium, ipratropium) are considered **first-line agents** and provide **significant benefit** in improving lung function and reducing exacerbations in **chronic obstructive pulmonary disease (COPD)**. - Their efficacy in COPD is often **superior** to beta-agonists for long-term maintenance therapy due to the prominent role of cholinergic tone in COPD bronchoconstriction. *Are better suited for control of an acute attack of asthma* - **Short-acting inhaled beta-2 adrenergic agonists** are the **drug of choice** for the rapid relief of acute asthma symptoms due to their quick onset of action. - **Inhaled anticholinergics** like **ipratropium** have a slower onset and are generally used as **adjunctive therapy** or for patients unable to tolerate beta-agonists during acute exacerbations.
Explanation: ***phenylephrine (alpha agonist)*** - **Phenylephrine** is a direct-acting **alpha-1 adrenergic agonist** that causes contraction of the **pupillary dilator muscle**, leading to **mydriasis** (pupil dilation). [1] - It is frequently used clinically to dilate pupils for **ophthalmologic examinations** due to its selective action on alpha-1 receptors in the eye. [2] *neostigmine (cholinesterase inhibitor)* - **Neostigmine** inhibits acetylcholinesterase, increasing acetylcholine at the neuromuscular junction and muscarinic receptors. This leads to **miosis** (pupil constriction), not mydriasis. - Its ophthalmic use is primarily for treating **glaucoma** by improving aqueous humor outflow through cholinergic effects on the ciliary muscle. *phentolamine (alpha blocker)* - **Phentolamine** is a **non-selective alpha-adrenergic antagonist** that blocks both alpha-1 and alpha-2 receptors. - Alpha-1 receptor blockade in the eye would relax the pupillary dilator muscle, leading to **miosis** or prevention of mydriasis, not its induction. *mecamylamine (ganglionic blocker)* - **Mecamylamine** is a **ganglionic blocker** that antagonizes nicotinic receptors in both sympathetic and parasympathetic ganglia. - Blocking parasympathetic ganglia can cause some mydriasis, but ganglionic blockers have widespread, non-selective autonomic effects and are not primarily used for isolated mydriasis.
Explanation: ***Aconite poisoning*** - **Hippus**, characterized by alternating **pupillary constriction and dilation**, is a hallmark of aconite poisoning. - This unusual pupil activity results from the **neurotoxic effects** of aconite on the autonomic nervous system. *Opioid poisoning* - Opioid poisoning typically causes characteristic **pinpoint pupils (miosis)** due to parasympathetic overstimulation. - Hippus is not a feature of opioid toxicity. *Neuromuscular blocking agent poisoning* - Neuromuscular blocking agents primarily affect the **skeletal muscles**, leading to **paralysis** but generally do not directly impact pupil size or reactivity. - Pupils usually remain **mid-dilated and fixed** in severe paralysis, but not hippus. *Belladonna poisoning* - Belladonna (atropine) poisoning causes **mydriasis (dilated pupils)** due to its anticholinergic effect, blocking parasympathetic activity. - The pupils are typically fixed and dilated, not exhibiting hippus.
Get full access to all questions, explanations, and performance tracking.
Start For Free